MDM2 downregulation is necessary for CDK4/6 inhibitor therapy-induced senescence in a variety of cancer cell lines, and the loss of MDM2 is observed post palbociclib treatment in patients with WD/DDLS who have prolonged periods of PFS [18]. This evidence concerns the gene CDK4 and Wilson disease.